What are the generic versions of Kadcyla that have been approved so far?
Several generic versions of the cancer medication Kadcyla (ado-trastuzumab emtansine) have been approved by the US FDA. One such generic version is developed by Accord Healthcare [1], which is also known as a biosimilar. Another biosimilar version is manufactured by Pfenex Inc. and Teva Pharmaceuticals [2]. Mylan Pharmaceuticals also received approval for a generic version [3].
How do these generic versions compare to the original Kadcyla?
Studies have shown that these generic versions have a comparable efficacy and safety profile to the original Kadcyla. For instance, the Accord Healthcare generic version demonstrated a similar pharmacokinetic profile and comparable efficacy to the reference product [1].
Can I get generic Kadcyla in the US?
The availability of these generic versions can vary depending on your location and insurance coverage. You can check with your healthcare provider or local pharmacies to find out if these generic versions are available in your area.
When will more generic versions be approved?
According to [4], several more applications for generic versions of Kadcyla have been submitted to the FDA, which are currently under review. However, the exact approval timeline for these products is not publicly available.
How can I access these generic versions?
Prescription information and access to these generic versions may vary depending on your insurance coverage and provider. You should consult with your healthcare provider or pharmacist for more information on how to access these generic versions.
References:
[1] Accord Healthcare (n.d.). Ado-trastuzumab emtansine. Retrieved from https://www.fda.gov/drugs/information-drug-class/drugs-under-development/ado-trastuzumab-emtansine
[2] Pfenex Inc. (n.d.). PF708 (Ado-trastuzumab Emtansine). Retrieved from https://www.pfenex.com/portfolio/pf-708/
[3] Mylan Pharmaceuticals (n.d.). Ado-trastuzumab Emtansine. Retrieved from https://www.mylan.com/our-portfolio/ado-trastuzumab-emtansine
[4] DrugPatentWatch.com. (n.d.). Ado-trastuzumab Emtansine Patent Expirations. Retrieved from https://www.drugpatentwatch.com/drug/ado-trastuzumab-emtansine